Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IV, Open, Multicentre, Single-arm Study to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression.

NCT03693508 is registered in ClinicalTrials.gov with Fundacion SEIMC-GESIDA as lead sponsor.

NCT NCT03693508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03693508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IV, Open, Multicentre, Single-arm Study to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression.
Lead sponsor
Fundacion SEIMC-GESIDA
Phase
Phase 4
Overall status
Completed
Start date
April 13, 2018
Completion date
May 28, 2020
Enrollment
50 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections, severe immunosuppression